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Vascular disrupting agents (VDAs) cause tumour blood vessels to collapse and this strategy kills tumour cells 
indirectly by rapidly cutting of their blood supply1. CA4P (combretastatin-A4 disodium phosphate), is a mem-
ber of the tubulin-binding family of VDAs, and has been tested extensively in preclinical tumour models2–4 and 
also in the clinic5,6. However, CA4P and other tubulin-binding VDAs have not yet gained FDA approval for the 
treatment of cancer despite resulting in some clinical responses when combined with additional treatments of 
chemotherapy or anti-angiogenic agents7.
Even though this area has been researched extensively for almost three decades, the molecular mecha-
nisms through which CA4P and other tubulin-binding VDAs cause tumour blood vessels to collapse are still 
not fully understood8,9. he extent to which tumours respond to this type of therapy is also extremely variable 
and although progress has been made in establishing the factors that govern tumour susceptibility to VDAs10,11 
there are still substantial gaps in our knowledge. At the cellular level, the binding of CA4P to β-tubulin disrupts 
endothelial microtubules, and this process rapidly activates molecular signalling pathways that modify the actin 
cytoskeleton and the morphology of endothelial cells, thereby severely compromising their barrier function8,12. 
RhoA-GTPase and its target kinase, Rho kinase (ROCK), are members of a major signalling pathway activated 
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by CA4P in endothelial cells ater microtubules are disrupted8. CA4P-activates RhoA/ROCK-mediated actino-
myosin contractility and actin reorganisation through phosphorylating target protein myosin light chain (MLC), 
causing stress ibres to form. In some cells ROCK-dependent contractility drives a characteristic “membrane 
blebbing” morphology. In blebbing cells, focal adhesions are disrupted, highly contractile stress ibres misassem-
ble into a spherical network surrounding the cytoplasm and numerous actin-rich surface blebs develop8. CA4P 
also disrupts endothelial cell-to-cell VE-cadherin junctions13 and within minutes the permeability of monolayers 
rises through processes that are Rho/ROCK dependent8. he efects of CA4P on endothelial morphology and 
permeability are postulated to contribute to tumour vascular collapse, which occurs within minutes ater tumours 
are treated with the drug2,14. More recently, we showed that CA4P activates ROCK in vivo and ROCK is required 
for full tumour vascular disrupting activity9 thus providing the irst evidence that signalling pathways identiied 
in vitro relate to the drug’s rapid in vivo mechanism of action.
Most solid tumours contain regions of hypoxia of variable severity15,16. Tumours become hypoxic because 
the demands for oxygen placed by the rapidly proliferating cancer cells cannot be met by angiogenesis and the 
resulting abnormal tumour blood supply17. Poorly perfused regions in a tumour may also be low in nutrients 
such as glucose, exacerbated by high glucose uptake and consumption rates18. Tumour cells are well adapted to 
survive under low oxygen conditions19, and despite retaining functional mitochondria, they favour glycolysis for 
generating ATP by converting glucose to pyruvate and lactate, even if suicient oxygen is present, a phenome-
non known as the ‘Warburg efect’20. Rather surprisingly, endothelial cells from normal as well as pathological 
tissues also use glycolysis as a means of generating ATP and are less dependent on oxidative phosphorylation for 
their energy supplies21. Both hypoxia and energy depletion are sensed by the master switch molecule adenosine 
monophosphate protein kinase (AMPK). AMPK is a serine/threonine enzyme that becomes phosphorylated 
and activated when oxygen levels are low or when ATP levels drop and the ratio of AMP/ATP rises22. AMPK has 
many functions including a key role in regulating metabolism. Under low energy conditions it functions mainly 
to conserve energy and promote ATP production through decreasing anabolic processes such as protein and lipid 
biosynthesis and by increasing glucose uptake. AMPK also has functions that do not directly relate to metabolism 
and has been implicated in the regulation of pathways associated with the remodelling of the cytoskeleton23,24.
While severe hypoxia makes cells resistant to radiotherapy and a number of conventional chemotherapy 
drugs25, it is not known whether tumour response to tubulin binding VDAs is inluenced by hypoxia. Because 
VDAs are more efective at eradicating the central regions of tumours that tend to be more hypoxic, while the 
well oxygenated tumour periphery is generally resistant26, there is a general assumption that these drugs work 
better under hypoxia. However, supporting experimental evidence for this is lacking. Tumours become even more 
hypoxic and nutrient depleted following VDA-induced vascular shutdown, which is a potential drawback to this 
type of treatment if followed by conventional therapy or if hypoxic but surviving cells become more aggressive via 
hypoxia-driven gene expression10,26,27.
In this study we analyse the signalling activity of CA4P in conditions of hypoxia and energy depletion in 
endothelial cells in culture. We found that prolonged and severe hypoxia is a regulator of CA4P signalling, 
cytoskeletal remodelling and permeability rise. he efects of hypoxia were nevertheless reversible and normal 
endothelial responses to CA4P could be restored rapidly following re-oxygenation. he cytoskeletal and signal-
ling efects of hypoxia were mimicked by glucose depletion or by reducing ATP levels in the cells with inhibitors 
of glycolysis and oxidative phosphorylation. Furthermore, we show that although AMPK is strongly activated 
by hypoxia, glucose deprivation and inhibitors of endothelial metabolism, its activation per se is not suicient to 
regulate CA4P signalling.

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Endothelial cells were exposed to varying levels of oxygen in individually gassed humidiied chambers main-
tained within the anaerobic chamber of a hypoxia station. Control cells were maintained in a parallel chamber in 
21% O2 to ensure that efects of gas low and humidity were controlled accurately. Cells were treated with CA4P 
within the main anaerobic chamber and then returned to their corresponding individually gassed boxes for a fur-
ther 15 min. he activity of CA4P was initially measured by analysing dually phosphorylated myosin light chain 
(pMLC), a target of ROCK8. Hypoxia (0.1%, 1% or 5% O2) for 1–5 hours had no signiicant efect on either basal 
or CA4P-induced levels of pMLC (data not shown). However, under prolonged hypoxia (1% O2 for 14 h), basal 
levels of pMLC remained the same as in normoxia but the induction of pMLC by CA4P was signiicantly attenu-
ated (Fig. 1a,f). Under extreme hypoxic conditions (0.1% O2 for 14 h), basal pMLC was reduced to very low levels 
and CA4P did not induce it further (Fig. 1a,f). Levels of total MLC protein were unafected and similarly, RhoA 
and ROCK isoform ROKa (ROCK2) levels were not signiicantly changed by hypoxia (Fig. 1a), so transcriptional 
regulation of these key proteins of the pathway was unlikely to be the cause of the observed reduction in MLC 
phosphorylation. In parallel with a reduction in MLC phosphorylation, the phosphorylation of extracellular reg-
ulated kinases (pERK1/2) was induced in 1% O2 while their levels dropped signiicantly in 0.1% O2 (Fig. 1a). In 
parallel, levels of phosphorylated heat shock protein-27 (pHSP27), a stress-induced protein and regulator of actin 
remodelling28 rose in hypoxia (Fig. 1a). Cell viability tended to decrease ater prolonged severe hypoxia, although 
not signiicantly (Fig. 1b). hese results agree with previous reports showing that endothelial cells are relatively 
resistant to hypoxic-induced cell death29,30. herefore, the observed reduction in the ability of cells to respond to 
CA4P could not be attributed to cell death. Indeed, cells regained their responsiveness to CA4P upon re-oxygen-
ation following severe hypoxia (Fig. 1c,f). Levels of pERK1/2 were also restored although pHP27 remained high 
until at least 60 min ater re-oxygenation.
Upstream of ROCK, levels of active RhoA, measured by pull down assays were reduced under severe hypoxia 
(Fig. 1d,e). CA4P induced the activation of RhoA in 21% O2 as expected
31 but failed to do so under severe hypoxic 
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conditions, thus demonstrating that the loss of active ROCK signalling was due to inactive/inactivatable RhoA, 
upstream of the pathway.
 ?Ǧǡ
Ǥ As shown previously, CA4P causes a rapid rise in endothelial monolayer per-
meability through Rho-ROCK dependent mechanisms8. However, endothelial monolayers were signiicantly less 
permeable to CA4P in hypoxia than in normoxia (Fig. 2a). In parallel, VE-cadherin cell-cell junctions responsible 
for maintaining barrier function, were also signiicantly less disrupted under hypoxia (Fig. 2b). Endothelial cells 
retract ater CA4P and become contractile8. In hypoxia, monolayers remained intact although the cell cytoplasm 
appeared thin and translucent (Fig. 3a). Highly contractile ‘blebbing’ cells that develop soon ater exposure to 
CA4P8 did not form under hypoxia (Fig. 3a,b) and this correlated with reduced levels of pMLC (see Fig. 1a) and 
reduced permeability. Despite complete loss of pMLC, actin stress ibers persisted under severe hypoxia (Fig. 3b), 
potentially driven by the high activity of pHSP27 (see Fig. 1a) which is known to cause stress ibre formation also 
in hypoxia32.

ơ ?
Ǥ To investigate the efects of energy depletion on the response to CA4P, conluent cultures were 
transferred to glucose-free DMEM supplemented with dialysed FCS. Control cultures were maintained in similar 
medium but containing glucose. Cells were exposed to hypoxia or 21% O2 and 5 hours later were treated with 
CA4P. Hypoxia alone at this time point had no detectable efect on pMLC or its induction by CA4P (Fig. 4a,b). 
Glucose deprivation reduced both basal and CA4P-induced levels of pMLC. Under hypoxia, the efects of glucose 
deprivation were signiicantly enhanced as basal levels of pMLC declined further, and CA4P failed to induce 
pMLC. Glucose deprivation, and to a lesser extent hypoxia, caused the phosphorylation of AMPK and its target 
Figure 1. Hypoxia and hypoxia followed by re-oxygenation alter RhoA-ROCK and MAPK signalling and 
response to CA4P in endothelial cells. (a) Conluent endothelial cells were exposed to varying oxygen levels 
for 14 h and then CA4P (1 µM) or vehicle (PBS) were added for a further 15 min. Cells were analysed for the 
expression and/or phosphorylation of the indicated proteins. (b) Conluent cells were exposed to either 21%, 1% 
or 0.1% O2 for 14 h and then total and viable cells were counted. (c) Cells were exposed to 21% or 0.1% O2 as in 
(a) and then either immediately treated with CA4P (1 µM) or vehicle for 15 min or returned to a normal oxygen 
incubator for 30 or 60 min to re-oxygenate (hypoxia-re-oxygenation, H/R) before they were treated with CA4P. 
(d) Cells maintained either in 21% or 0.1% O2 for 14 h, were exposed to CA4P as in (a) and active GTP-bound 
RhoA was analysed in pull-down assay. (e) Active Rho was normalised to total RhoA and expressed as fold 
increase over control cells in 21% O2. (f) pMLC data from (a) and (c) was normalised to actin and expressed 
as fold increase over control untreated cells maintained in 21% O2. All data were analysed by one-way Anova 
followed by a Tukey post-test. Values are means ± SEM (*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001). 
All blots and analyses are representative of 3–7 independent experiments.
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pACC, suggesting that the ratio of AMP/ATP increased in the cells (Fig. 4a). Contractile blebbing cells did not 
form in glucose-depleted media in hypoxia (0.1% O2) while blebbing cells were present in cultures where glucose 
was present (Fig. 4c). Interestingly, microtubules also appeared more resistant to CA4P-mediated disruption in 
cells deprived of glucose in hypoxia.

 ?Ǧ-
Ǥ To explore further the requirement for ATP in maintaining ROCK 
signalling, endothelial cells were exposed to the glycolysis inhibitor 2DG (20 mM) or the mitochondrial electron 
transport chain inhibitor rotenone (0.5 µM) 2 hours before CA4P; these were conditions previously shown to 
reduce intracellular ATP levels in HUVECs33. Individually, 2DG and rotenone signiicantly reduced basal and 
CA4P-induced levels of pMLC (Fig. 5a,b). pMLC was undetectable in control and CA4P-treated cells exposed 
to 2DG and rotenone simultaneously. Similar results to those obtained with rotenone were obtained with oli-
gomycin, a diferent mitochondrial respiration inhibitor (not shown). AMPK was phosphorylated/activated in 
cells exposed to 2DG and/or rotenone. Levels of pHSP27 rose in the presence of either 2DG or rotenone, but 
in cells exposed to both inhibitors simultaneously, pHSP27 levels dropped down to basal (Fig. 5a). Similarly, 
pERK1/2 levels were reduced when energy levels were depleted. Τhe efects of ATP depletion on signalling were 
reversed when normal metabolism was restored by removing 2DG and rotenone and allowing the cells to recover 
in fresh culture media for 15 or 30 minutes (Fig. 5a,b). Levels of pMLC and pERK1/2 were restored while pAMPK 
declined back to basal (Fig. 5a). pHSP27 levels rose during the recovery period, possibly as a consequence of 
ischaemia/reperfusion stress. Similar to hypoxia, GTP-bound active RhoA was signiicantly reduced in cells 
exposed to 2DG and rotenone suggesting that ATP depletion interferes with the Rho-GTPase activation cycle 
(Fig. 5c,d).
Figure 2. Hypoxia prevents loss of endothelial barrier function and VE-cadherin disruption mediated by 
CA4P. (a) Endothelial cells cultured to conluence in 3 µm pore size ilter inserts set in companion 24-well 
plates were exposed to the indicated oxygen levels for 14 h and then to CA4P (1 µM) for an further 15 min. 
FITC dextran difusion through the monolayers during 30 min, was expressed as fold change over control 
untreated cells maintained in 21% O2.. Results are from 5–7 independent experiments. Data were analysed by 
one-way Anova followed by a Tukey post-test. Values are means ± SEM (*p < 0.05, **p < 0.01, ***p < 0.001, 
****p < 0.0001). (b) Cells in 21% or 0.1% O2 for 14 h were treated with CA4P as in (a) and then ixed and 
stained for VE-cadherin.
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Microtubules were resistant to CA4P disruption in cells treated with 2DG (compare images in Fig. 4c top 
panels to images in Fig. 6). When 2DG was combined with rotenone then microtubules became totally resistant 
to disruption while actin ilaments were totally dissociated/absent (Fig. 6, lower panel). Actin ilaments were 
restored rapidly following a period of recovery in fresh cell culture media (Fig. 6, lower panel). Similarly, micro-
tubule sensitivity to CA4P was also re-established when ATP levels were restored. hese results show that energy 
levels/ATP determine the endothelial cytoskeleton response to CA4P.
 ?Ǥ AMPK exists as a heterotrimeric protein consist-
ing of catalytic α and regulatory βγ subunits forming an AMPKα2β2γ3 complex that plays a central role in the 
regulation of cell metabolism. In addition, AMPK is known to inluence signalling pathways associated with the 
cytoskeleton23,34 and in particular it was reported to regulate the activity of several members of the Rho-GTPase 
family35. In the next experiments, a number of pharmacological agents that activate AMPK through distinct 
mechanisms were used in order to establish whether AMPK itself played a direct role in altering RhoA/ROCK 
activation by CA4P. AMPK can be activated by agents that raise AMP/ATP levels or by compounds that directly 
bind it and act through conformational changes36. AICAR, a widely used small molecule AMPK activator, is con-
verted to the AMP mimetic ZMP that binds to the γ subunit of AMPK and causes conformational changes lead-
ing to sustained phosphorylation of hr-172 on the α subunit37. Several other small molecule activators of AMPK 
include the Abbott Laboratories compound A-76966238, salicylate39, PT140 and ZLN02441 which are all reported 
to activate AMPK allosterically by binding directly to diferent sites on AMPK subunits. Metformin on the other 
hand activates AMPK indirectly by increasing the AMP/ATP ratio42. AICAR or A-769662, caused a substantial 
activation/phosphorylation of AMPKα and ACC in endothelial cells (Fig. 7a). AICAR signiicantly reduced basal 
levels of pMLC and there was also a trend for a reduction in pMLC levels in cells subsequently treated with 
CA4P, compared to cells treated in the absence of AICAR; however, the data did not reach statistical signiicance 
(Fig. 7a,b). A-769662, metformin, ZLN024, salicylate and PT1 did not alter either the basal or CA4P-induced 
pMLC levels despite being potent at activating AMPK (Fig. 7a,b).
In the next series of experiments, cells were exposed to each of the AMPK activators together with 10 mM 
2DG. At this dose, 2DG in the absence of another AMPK activator, did not cause a substantial change in basal or 
CA4P-induced levels of pMLC. However, when combined with AICAR, 2DG synergised to substantially reduce 
pMLC (Fig. 8a,b). Because AICAR could potentially increase the uptake of 2DG and therefore further deplete 
the cells of ATP we also exposed cells to AICAR and rotenone. his combination also caused a complete reduc-
tion in pMLC (Fig. 8a,b) implying that an enhanced uptake of 2DG was an unlikely cause of the observed 2DG 
and AICAR synergism. Similar to AICAR, metformin, salicylate and PT1, also caused a substantial reduction in 
pMLC when combined with 2DG but this efect was not reproduced by A-769662 or ZLN024 (Fig. 8a,b). hese 
Figure 3. Hypoxia prevents the disruption of endothelial monolayer integrity and actin ilament remodelling 
mediated by CA4P. (a) Phase contrast images of cells maintained either in 21%, 1% or 0.1% O2 for 14 h, 
and exposed to CA4P for 15 min. (b) cells were treated as in (a) and then ixed and stained with Texas-red 
phalloidin. Blebbing cells are indicated with white arrows in (a,b).
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data show that each pharmacological activator of AMPK inluences Rho/ROCK signalling via unique mecha-
nisms that are independent of activated AMPK itself.

In this study we found that hypoxia and energy depletion, diminished the ability of endothelial cells to respond 
to CA4P. Using the induction of phosphorylation of ROCK-efector MLC, as a measure of the activity of CA4P8,9, 
we showed that hypoxia, or conditions that depleted the cells of energy/ATP, reduced basal levels of pMLC and/
or prevented the induction of MLC phosphorylation by CA4P. he decline in pMLC under hypoxia was paral-
leled by a reduction in RhoA-GTPase activity which is upstream of ROCK and MLC phosphorylation. Reduced 
remodelling of the actin cytoskeleton and reduced actinomyosin contractility, correlated with the extent of energy 
depletion. In hypoxia, the decline in pMLC was dependent on both the duration as well as the severity of oxygen 
depletion. Glucose deprivation caused a much faster reduction in pMLC compared to that caused by hypoxia, 
while hypoxia synergised with glucose deprivation and reduced pMLC levels further. Inhibitors of oxidative phos-
phorylation and glycolysis also reduced pMLC levels, and when combined in order to completely deplete cells 
of ATP, there was profound loss of pMLC and actin ilaments were totally disrupted. Our data therefore pro-
vide strong evidence that the activity of the RhoA-ROCK-pMLC signalling axis and the regulation of the actin 
cytoskeleton, and hence the response of endothelial cells to CA4P, are directly dependent on intracellular ATP 
levels.
Many diverse signalling activities are regulated by hypoxia in endothelial and other cells. Specifically, 
hypoxia-mediated regulation of Rho family members, as seen by changes in their gene and protein expression 
levels, and/or through changes in their GTPase activities has been reported43. However, the activity and levels 
of expression of Rho proteins have been shown to either increase or decrease in hypoxia. Wojciak-Stothard et 
al.44 showed that in porcine endothelial cells RhoA-GTPase activity increased and peaked between 1–2 hours at 
3% O2 and then declined back to basal levels by 4 hours. Similarly, in human pulmonary endothelial cells, active 
RhoA and RhoB were signiicantly elevated in 2% O2 and in parallel there was an increase in RhoA and RhoB 
gene and/or protein expression that peaked at early time points and reverted to basal levels by 4 hours45. Unlike 
Wojciak-Stohard et al.44,45, we found no signiicant changes in the extent of MLC phosphorylation and the ability 
of CA4P to phosphorylate it further at early time points (1–5 hours) following the initiation of hypoxia, suggest-
ing that there were no substantial changes in the activity of RhoA or RhoB GTPases under our conditions. We 
Figure 4. Hypoxia and glucose deprivation synergise to inhibit ROCK signalling in endothelial cells. Conluent 
cultures were switched to normal DMEM or DMEM without glucose (Glc), supplemented with 5% dialysed 
FCS and then immediately exposed to 21%, 1% or 0.1% O2. Ater 5 h, cells were treated with CA4P (1 µM) for a 
further 15 min. (a) Cell extracts were analysed for the indicated proteins. (b) pMLC was normalised to actin and 
expressed as fold increase over control cells maintained in 21% O2. (c) Cells were stained for F-actin with Texas 
Red phalloidin (red) and β−tubulin (green). Blebbing cells are indicated with white arrows. Results are from 
3 independent experiments. Data were analysed by one-way Anova followed by a Tukey post-test. Values are 
means ± SEM (*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001).
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used diferent endothelial cells and hypoxia conditions than Wojciac-Stothard et al. and this could potentially 
explain our diferent indings. On the other hand, Solodushko et al.46 showed that when rat and human pulmo-
nary microvascular endothelial cells were cultured in 5% O2 compared to 21% O2 they formed tighter junctions 
and were less permeable due to a reduction in RhoA-GTPase activity. Recently, Leinhos et al.47 showed that 
Rho-GTPase activity was markedly downregulated in ibroblasts exposed to 1% oxygen. Rho-GTPases are regu-
lated by GEFs (guanine exchange factors) that promote exchange of GDP for GTP and activate Rho proteins, and 
by GAPs (guanine activating factors) that facilitate the exchange of GTP for GDP that turn of the activity of Rho 
proteins. Reduced activity of RhoA was attributed to a selective induction in GAP ARHGAP29 expression under 
hypoxia47. It is possible that under our prolonged and severe hypoxic conditions (14 h at 0.1 or 1% O2), or under 
conditions of total energy depletion, a GAP protein(s) was induced, which may have contributed to the reduc-
tion in Rho-GTPase activity we reported here. his would also imply that GAP levels declined rapidly following 
re-oxygenation or recovery from ATP depletion in our system.
A drop in ATP levels in hypoxia can explain our results and there are several lines of evidence to support this. 
Low supplies of oxygen limit mitochondrial oxidative phosphorylation and reduce intracellular ATP levels as 
shown previously in HUVECs in 0.5 or 1.5% O2 (levels dropped by ≈27% and 20% respectively ater 2 hours)
33. 
Selective inhibition of RhoA-GTPase as a consequence of ATP depletion was previously demonstrated in epithe-
lial cells48,49. he efects of ATP reduction were selective for RhoA, and not for other members of the Rho family, 
namely Rac1 and Cd42, and it was proposed that the preferential selectivity for RhoA was due to efects on spe-
ciic GEFs and GAPs. Additionally, in astrocytes, ATP activated RhoA rapidly, providing direct evidence for the 
involvement or ATP in the regulation of Rho-GTPases50. Endothelial cells can use glycolysis to generate ATP and 
limited supplies of nutrients and glucose oten accompany hypoxia in vivo. We hypothesised that if the reduction 
in RhoA/ROCK activity in hypoxia was due to lower levels of ATP, then glucose deprivation would mimic the 
efects of hypoxia. Indeed, pMLC downregulation was substantial in glucose-deicient media and pMLC was 
further reduced by exposure to hypoxia suggesting that the two synergised to reduce ATP levels further. Indeed, 
Quintero et al.33 showed that if 2DG and hypoxia were combined, then by 2 hours, ATP levels were substan-
tially reduced (they dropped by ≈63% in 1.5% O2 and by ≈75% in 0.5% O2), and therefore our results could be 
explained by a further reduction in ATP levels when glucose deprivation and hypoxia were combined. Levels of 
pMLC also dropped by inhibiting either glycolysis or oxidative phosphorylation under identical conditions to 
those used by Quintero et al.33. A more drastic and profound loss of pMLC, however, occurred ater exposing the 
cells simultaneously to 2DG and rotenone, these being conditions that led to almost total ATP loss in HUVEC 
Figure 5. Inhibitors of glycolysis and oxidative phosphorylation inhibit pMLC signalling. (a) Conluent 
endothelial cultures were incubated with vehicle control (Ctr), 2DG (20 mM) or 0.5 µM rotenone (Rot) or 2DG 
plus rotenone for 1 hour. Cells were treated with CA4P (1 µM, 15 min) either immediately or ater the cells were 
incubated in fresh media for 15 or 30 min. Cell extracts were analysed for the indicated proteins. (b) pMLC 
was normalised to actin and expressed as fold increase over untreated cells maintained in control media. (c) 
Cells were treated with 2DG and rotenone as in (a) and GTP-bound RhoA was analysed in pull-down assay. (d) 
Active Rho was normalised to total RhoA and expressed as fold increase over control cells in 21% O2. Results 
are from 3–7 independent experiments. Data were analysed by one-way Anova followed by a Tukey post-test. 
Values are means ± SEM (*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001).
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(ATP levels dropped by ≈95% in 2 hours)33. Conversely, when ATP levels were restored by allowing the cells to 
recover in fresh full media, then a rapid recovery of pMLC signalling and cytoskeletal structures was seen (Figs. 5 
and 6). Our data therefore point to a direct link between intracellular levels of ATP, pMLC and consequently actin 
regulation.
he energy sensor kinase AMPK itself has been implicated in the regulation of the cytoskeleton23,24,35. Xing 
et al.35 showed that lipopolysaccharide-induced RhoA/ROCK activation in lung endothelial cells was inhibited 
by the AMPK activator AICAR. We sought to establish whether activated AMPK was the common link between 
lowered ATP and loss of ROCK signalling. We hypothesised that if AMPK was directly responsible for lowering 
ROCK activity, then pharmacological activators of the kinase would mimic the efects of low ATP. However, all 
the pharmacological AMPK activators we tested caused robust activation of AMPK, but only AICAR caused a 
signiicant reduction in basal levels of pMLC. Furthermore, AICAR and the other AMPK activators that were 
tested failed to alter the induction of pMLC by CA4P (see Fig. 7). hese results suggest that AMPK activation 
per se is insuicient to downregulate pMLC and regulate the cytoskeleton. AICAR generates the AMP-mimetic 
ZMP, which accumulates at high concentrations, and binds competitively at the AMP/ATP/ADP regulatory site 
on AMPKγ to activate the kinase37. Metformin inhibits mitochondrial complex I and alters the ratio of AMP/
ATP, and this in turn activates AMPKγ through binding of AMP to the AMP/ATP/ADP regulatory binding site42. 
However, A-769662 does not generate AMP, binds AMPKγ at a diferent site and activates the enzyme allosteri-
cally38. Similarly, ZLN024, PT1 and salicylate are reported to activate AMPK allosterically. We found that while 
metformin and AICAR synergised with 2DG to substantially reduce pMLC levels in endothelial cells, A-79662 
did not. Salicylate and PT1 also synergised with 2DG to reduce pMLC while ZLN024 behaved similar to A-79662. 
Being direct allosteric activators of AMPK, salicylate and PT1 were not initially considered to inluence AMP and 
Figure 6. Inhibitors of glycolysis and oxidative phosphorylation inhibit F-actin ilaments and stabilise 
microtubules against disruption by CA4P. Conluent endothelial cultures were incubated with vehicle control 
(Ctr) or 2DG (20 mM) or 0.5 µM rotenone (Rot) or 2DG plus rotenone for 1 hour. Cells were treated with 
CA4P (1 µM, 15 min) either immediately or ater they recovered in fresh media for 30 min. Cells were ixed and 
double-stained with Texas Red phalloidin for F-actin (red) and β-tubulin (green).
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ADP. Nevertheless, these agents were subsequently shown to also alter mitochondrial respiration and increase 
the AMP/ATP ratio in cells39,51. It appears therefore, that only the AMPK activators that can also generate AMP, 
or the AMP mimetic ZMP in the case of AICAR, are capable of synergising with the metabolism inhibitors and 
alter RhoA/ROCK signalling. It is therefore likely that sensing of lowered ATP levels (or an increase in the ratio 
of AMP/ATP) beyond a certain threshold translates to a reduction in RhoA/ROCK activity, through an as yet 
unidentiied mechanism(s) that is nevertheless likely to be independent of AMPK.
Figure 7. Pharmacological activators of AMPK do not inluence pMLC induction by CA4P. (a) Conluent 
endothelial cultures were either let untreated as controls (Ctr) or incubated with AMPK activators: AICAR 
(1 mM), A-769222 (A76, 300 µM), salicylate (SAL, 5 mM), ZLN024 (ZLN, 40 µM), or PT1 (20 µM) for 1 hour, 
or metformin (MET, 2 mM) for 14 h. CA4P (1 µM) was then added for 15 min and cell extracts were analysed 
for expression of the indicated proteins. (b) pMLC was normalised to actin and expressed as fold increase over 
control untreated cells. Results are from 3–7 independent experiments. Data were analysed by one-way Anova 
followed by a Tukey post-test. Values are means ± SEM (*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001).
Figure 8. Only AMPK activators that generate AMP synergise with 2DG or rotenone to block CA4P-mediated 
ROCK signalling. (a) Cells were treated with AMPK activators: AICAR (1 mM), A-769222 (A76, 300 µM), 
salicylate (SAL, 5 mM), ZLN024 (ZLN, 40 µM) or PT1 (20 µM) for 1 hour, or metformin (MET, 2 mM) for 
14 hours. 2DG (10 mM) or rotenone (Rot, 0.25 µM) were added to the cells at the same time as the AMPK 
activators except for in the case of metformin when 2DG was added during the last hour of incubation. CA4P 
(1 µM) was added for a further 15 min and cell extracts were analysed for pMLC. (b) pMLC was normalised 
to actin and expressed as fold increase over control cells without any drug treatments. Results are from 3–5 
independent experiments. Data were analysed by one-way Anova followed by a Tukey post-test. Values are 
means ± SEM (*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001).
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ROCK-dependent signalling by CA4P induces actin remodelling, and contractility-driven membrane ‘bleb-
bing’8. Under hypoxic conditions, highly contractile ‘blebbing’ cells did not form ater CA4P. he reduction in 
contractility was also associated with a profound reduction in VE-cadherin junctional disruption and reduced 
permeability to dextran. Similarly, if cells were deprived of glucose, then the development of highly contractile 
‘blebbing’ cells was abolished. However, stress ibers were present under hypoxic and glucose depleted conditions, 
even when pMLC levels were extremely low and cells would not be expected to form stress ibers. Hypoxia afects 
many signalling pathways and can alter stress response proteins including members of the mitogen activated pro-
tein family32. Indeed, hypoxia altered the phosphorylation of ERK1/2 and HSP27 in endothelial cells. Induction of 
pERK1/2 occurred at 1% O2 but levels dropped signiicantly at 0.1% O2, while HSP27 phosphorylation was more 
pronounced at 0.1% O2. When phosphorylated, ERK1/2 can protect HUVECs from ROCK-induced ‘blebbing’ as 
we showed before8, while activated HSP27 can promote actin ilaments and stress ibres to form in the absence of 
activated ROCK signalling. he phosphorylation status of HSP27 correlated with both absence of ‘blebbing’ and 
the presence of stress ibres seen ater hypoxia (Fig. 3b) when levels of active pMLC were low. Cells completely 
lost their stress ibres and pHSP27 if both glycolysis and oxidative phosphorylation were blocked, these being 
conditions of extreme ATP depletion (see Fig. 6). Previous reports showed a similar loss of actin ilaments/stress 
ibers in epithelial cells ater ATP depletion48.
Re-oxygenation, following hypoxia has been reported to result in changes in Rho protein-dependent signal-
ling. Wojciac-Stothard et al.44 showed that re-oxygenation increased Rac1-GTPase activity through the produc-
tion of ROS and reduced RhoA-GTPase activity in porcine endothelial cells, while in contrast, others showed that 
re-oxygenation increased levels of RhoA activity in porcine endothelial cells with a concomitant reduction in 
Rac1 activity52. We found that re-oxygenation restored the ability of CA4P to activate ROCK-mediated signalling 
and the ability of CA4P to activate it further. Both Rac and Rho-GTPases can be activated by ROS while Rac1 
itself can generate ROS through the activity of NADPH oxidase53. Rac1 and Rho antagonise each other54 so that 
a reciprocal balance between their GTPase activities exists. he precise consequences of ROS generation on the 
activities of individual members of the Rho-GTPase family are therefore likely to depend on the speciic cellular 
system, local stimuli or other factors. he rapid recovery of ROCK signalling by reoxygenation in our study can be 
explained by both an increase in ATP levels through restored mitochondrial activity as well as by ROS-dependent 
activation of RhoA signalling.
We also saw substantial changes in microtubule stability under conditions of energy depletion. Microtubules 
became totally resistant to CA4P disruption under conditions of severe ATP depletion (see Fig. 6). Similar efects 
of ATP depletion were previously reported for ibroblasts55. Hypoxia is also thought to regulate microtubule 
stability and render microtubules resistant to disruption56. Although we did not observe any substantial difer-
ences in the susceptibility of endothelial microtubules to CA4P when cells were maintained in hypoxia versus 
normal oxygen conditions (data not shown), we nevertheless observed more intact microtubules ater CA4P in 
glucose-deprived cultures concurrently exposed to hypoxia compared to cultures maintained in normal oxygen 
and glucose (see Fig. 4b). he mechanisms through which ATP depletion stabilises microtubules are unclear but 
may relate to regulation of tubulin by post-translational modiications such as tyrosination and acetylation or 
enhanced expression of proteins including ERG-155–57.
The microtubule cytoskeleton of endothelial cells is the initial target of CA4P and other similar VDAs. 
Induction of contractility and disruption of cell-cell junctions and permeability rise that occur soon ater the 
disruption of microtubules are considered important in vivo as part of the mechanism of vascular shutdown by 
CA4P and similar VDAs1. he changes we describe in this study under hypoxia and in conditions of energy deple-
tion may translate into resistance to CA4P in vivo. his is provided oxygen and ATP levels within the tumour 
vessels drop below a certain threshold required for eicient microtubule disruption and activation of ROCK 
signalling by CA4P. Intravascular hypoxia occurs in tumours through deiciencies in oxygen transport and ves-
sels can be hypoxic even if they are lowing58–60. Longitudinal gradients of oxygen develop and intravascular 
pO2 drops as red blood cells move further from a supplying arteriole and this can result in regions where the 
pO2 becomes very low
59. On the other hand, hypoxia may luctuate, so cycles of hypoxia and reoxygenation 
occur with frequencies of a few cycles per hour to days60. Depending on the kinetics of cycling hypoxia, intra-
vascular regions may remain poorly oxygenated for substantial periods of time61. Although our results do not 
explain why tumours that are generally considered hypoxic are more sensitive to VDAs than normal tissues, the 
consequences of frequent hypoxia-reoxygenation cycles may sensitise the vasculature to VDA-induced damage. 
Reactive oxygen species activate ROCK dependent mechanisms in the heart and other organs and are responsi-
ble for ischaemia-reperfusion injury62. Cycling hypoxia could therefore have a sensitising efect on the tumour 
vasculature to CA4P.
here are many factors within the tumour microenvironment that could potentially contribute to tumour sen-
sitivity to VDAs. Interactions between stroma and tumour cells within the tumour microenvironment as well as 
systemic efects could well impact on the outcome of this type of therapy. We found that immature blood vessels 
lacking adequate pericyte coverage are more sensitive to VDA disruption11. Research from our team also showed 
that the vascular damaging efects of CA4P could be signiicantly enhanced by inhibiting constitutive isoforms 
of nitric oxide synthase63. Further studies are required to establish whether response to VDAs is modiied by the 
continuously changing levels of oxygenation in tumours. If so, approaches to modify tumour oxygenation, similar 
to those undertaken for improving radiotherapy outcomes64, may also be explored as potential modiiers of VDA 
response.
1 1SCIENTIFIC REPORTS |         (2020) 10:9926  | ǣȀȀǤȀ ? ?Ǥ ? ? ? ?Ȁ ? ? ? ? ?Ǧ ? ? ?Ǧ ? ? ? ? ?Ǧ ?
www.nature.com/scientificreportswww.nature.com/scientificreports/

Ǥ Rotenone, AICAR (5-aminoimidazole-4-carboxamide riboside), A-769662, metformin, ZLN024 
and PT1 were purchased from Tocris and 2-deoxy-D-glucose (2DG) was purchased from Abcam. Oligomycin 
and antibodies to MLC, pMLC, pHSP27, pAMPKα, pACC were purchased from Cell Signaling Technology. 
Salicylate was purchased from Sigma. he anti-VE-cadherin and ROKα antibodies were from BD-Biosciences 
and the anti-RhoA antibody was from Merck Millipore. Glucose-free DMEM and dialysed serum were purchased 
from Gibco Life Technologies (Paisley, United Kingdom).
 ?Ǥ CA4P was synthesized using a modiied version of Lara-Ochoa’s protocol65. Alkyne 1 
was prepared via Corey-Fuchs methodology. he reaction proceeded smoothly to yield 1, in 79% yield, over 
three steps from isovanillin. he reaction was scalable to 130 mmol without afecting yield. Lara-Ochoa and 
co-worker had previously reported the copper-free Sonogashira coupling of the non-protected form of alkyne 
1, with 1-iodo-3,4,5-trimethoxybenzene in excellent yield65. Application of the reported conditions to 1 with 
1-bromo-3,4,5-trimethoxybenzene resulted in the isolation of diarylalkyne 2 in a yield of 95%. Conveniently, 
the silyl ether was cleaved under the reaction conditions to yield the free phenol. Conditions from the same 
authors facilitated the selective reduction of alkyne 2 to CA4 with titanium(IV) tetraisopropoxide and n-butyl 
lithium (nBuLi). However, subjection of 2 to these conditions resulted in incomplete conversion and an insepa-
rable mixture of starting material and product in our hands. It was found that, deprotonation of the phenol with 
an extra equivalent of nBuLi, before addition of the titanium reagent and further nBuLi, resulted in complete 
conversion of the starting material and isolation of CA4 in 96% yield, >98:2 Z:E. he crude product was of high 
enough purity to be taken forward to the next step without further puriication. CA4 was successfully phospho-
rylated with phosphorus oxychloride in dichloromethane. It was found that a “one pot” protocol, in which the ion 
exchange resin was added to the crude isolated phosphate monoester in water, resulted in product isolation in an 
87% yield ater recrystallization from acetone. he purity of the product by HPLC was determined to be >99%. 
herefore, CA4P was successfully synthesised, in gram quantities, in a 63% yield over 7 steps (Fig. 9).
Ǥ Human umbilical vein endothelial cells from pooled donors (Promocell, Germany) were grown 
on gelatin-coated culture dishes in ready-use Endothelial Cell Growth Medium (Promocell) supplemented 
with an additional 8% low endotoxin heat inactivated fetal calf serum (Invitrogen). Conluent monolayers were 
obtained by plating cells at a density of 2 × 104 cells/cm2 and allowing them to grow for up to 7 days. Cultures were 
used 3–4 days ater reaching conluence and were used for experiments for up to 5 passages. Assessment of cell 
viability was performed by the trypan blue exclusion method using the Biorad TC20TM automated cell counter.
Ǥ Cells were incubated under hypoxic conditions in a Don Whitley VA500 anaerobic 
workstation (Don Whitley, Shipley, West Yorkshire) modiied to accommodate individual sealed humidiied 
chambers. Each chamber was itted with an independent gas supply of 21%, 5%, 1% or 0.1% O2, with 5% CO2 
and balance of nitrogen. All gases were certiied to medical standards. he main workstation chamber was main-
tained as an anaerobic atmosphere so that when cultures were removed from their individual chambers for the 
addition of CA4P they were not exposed to oxygen. he O2 concentration in the chambers was determined using 
a hand-held O2 analyzer and O2 in cell culture media was checked using a Jenway 970 DO2 oxygen probe.
Figure 9. Scheme illustrating steps in CA4P synthesis.
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Ǥ To deplete cultures of glucose, monolayers 
were rinsed twice in glucose-free DMEM and then incubated in glucose-free DMEM supplemented with 5% 
dialysed FCS. In parallel, control cultures were treated in the same way except that glucose containing DMEM 
was used. ATP depletion was achieved by the addition of 2DG and/or rotenone to the cells without prior media 
change. To assess recovery from ATP depletion three consecutive media washes were performed and cells were 
incubated for a further 15–30 min in fresh media in a 37 °C incubator.
Ǧ
Ǥ he Active Rho Pull Down Detection Kit (hermo Scientiic) was used to 
assess the activation status of RhoA-GTPase according to the manufacturer’s instructions. Briely, proteins were 
extracted in lysis bufer supplied by the kit (ice cold and supplemented with protease inhibitors). Equal amounts 
(800 µg) of clariied protein were incubated with GST-Rhotekin-RBD and glutathione resin for 1 h at 4 °C. Active 
Rotekin-RBD-bound RhoA was eluted from the beads and analysed by western blotting using an anti-RhoA 
antibody supplied in the kit.
Ǥ Cell lysates were prepared by lysing the cells in 63 mM Tris-HLC pH 6.8 and 
2% SDS bufer. Extracts were further prepared in reducing Laemmli sample bufer (Bio-Rad) heated to 70 °C 
for ten minutes, resolved by electrophoresis on polyacrylamide gels and transferred to nitrocellulose or PVDF 
membranes. Membranes were probed with primary antibodies overnight at 4 °C followed by secondary antibod-
ies coupled to HRP (Dako). Immunoreactive bands were visualized using enhanced chemiluminescence with 
EZ-ECL (GeneFlow) and developed on blue autoradiography ilm. Films were scanned and imported into Adobe 
Photoshop, converted into Grayscale and levels were adjusted using the ‘Auto’ function. he relevant lanes were 
cropped and assembled into multi-panel Figures. All full-length uncropped blots are shown as supplementary 
data.
ƪǤ HUVECs were cultured on ibronectin-coated 
Permanox Lab-Tek chamber slides (Life Technologies, Paisley, United Kingdom) and stained for actin ilaments, 
microtubules and VE-cadherin junctions as we described before8. Immunoluorescence localization of β-tubulin 
and VE cadherin were performed simultaneously with F-actin staining using Texas Red conjugated phalloidin 
(Invitrogen). Cells were viewed with an Olympus BX microscope and images were captured using Cell^F sotware 
and processed using Adobe Photoshop.
Ǥ Diffusion of FITC-coupled 40 kDa dextran through 
endothelial monolayers was determined in HUVECs grown to conluence on ibronectin-coated culture inserts 
(3-µm pore size; 0.3 cm2 surface area) set into 24-well companion plates (BD Biosciences) as we described before8. 
Conluent cells on ilters were placed inside the chambers of the anaerobic workstation for a further 14 h before 
they were treated with CA4P for 20 min and then FITC-coupled dextran was added and media samples were 
collected from the lower compartment 30 min later. Fluorescence was quantiied using a Galaxy FLUOStar 
microplate reader and results are expressed as arbitrary luorescence normalized against values obtained from 
parallel control cells maintained in 21% O2.
Ǥ Data were analyzed by either unpaired t-test or one-way ANOVA followed by Tukey’s 
analysis for multiple comparisons using Prism 5 sotware (Graphpad sotware). A value of P < 0.05 was consid-
ered signiicant.
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